A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405
Akira Inoue(Tohoku University Hospital), T. Nukiwa(Tohoku University), Masako Harada(Quantitative BioSciences), Shinji Ogura(Tokyo Medical University), Toshiyuki Harada(Hokkaido hospital), Satoshi Oizumi(Hokkaido University), Osamu Ishimoto(Sendai Kousei Hospital), Hiroshi Yokouchi(National Hospital Organization Hokkaido Medical Center), Shinichi Fukumoto, Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Mariko Kanbe, Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiro Usui(Hokkaido University Hospital), Takuji Suzuki(Chiba University), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 37
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695